{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:51:45Z","timestamp":1793400705355,"version":"4.5.0"},"reference-count":110,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005629","name":"Takeda Pharmaceuticals America Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005629","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.cllc.2024.02.005","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T10:14:22Z","timestamp":1708164862000},"page":"285-318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["QT-Interval Prolongation, Torsades de Pointes, and Heart Failure With EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Systematic Review"],"prefix":"10.1016","volume":"25","author":[{"given":"Bilal","family":"Khokhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy","family":"Iglay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamika","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidia","family":"Rodriguez-Ormaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Spalding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Freedland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2024.02.005_bib0001","unstructured":"The top 10 causes of death: World Health Organization; 2020.Updated 9 December 2020. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death. Accessed 4 March 2024."},{"key":"10.1016\/j.cllc.2024.02.005_bib0002","unstructured":"2022 estimates: American Cancer Society Cancer Statistics Center; 2022.Available at: https:\/\/cancerstatisticscenter.cancer.org\/#!. Accessed 18 August 2022."},{"key":"10.1016\/j.cllc.2024.02.005_bib0003","doi-asserted-by":"crossref","first-page":"e13250","DOI":"10.1111\/ijcp.13250","article-title":"Incidence and outcomes of long QTc in acute medical admissions","volume":"72","author":"Mahmud","year":"2018","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.cllc.2024.02.005_bib0004","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jemermed.2017.08.073","article-title":"Prevalence and outcome of high-risk QT prolongation recorded in the emergency department from an institution-wide QT alert system","volume":"54","author":"Anderson","year":"2018","journal-title":"J Emerg Med"},{"key":"10.1016\/j.cllc.2024.02.005_bib0005","article-title":"Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review","volume":"6:e007724","author":"Porta-S\u00e1nchez","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cllc.2024.02.005_bib0006","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke statistics-2022 update: a report from the American Heart Association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cllc.2024.02.005_bib0007","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1186\/s12885-020-07487-9","article-title":"Impact of pre-existing cardiovascular disease on treatment patterns and survival outcomes in patients with lung cancer","volume":"20","author":"Batra","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cllc.2024.02.005_bib0008","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.lungcan.2015.01.006","article-title":"Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis","volume":"88","author":"Kravchenko","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2024.02.005_bib0009","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1010-7940(03)00093-9","article-title":"The impact of cardiovascular comorbidity on the outcome of surgery for stage I and II non-small-cell lung cancer","volume":"23","author":"Ambrogi","year":"2003","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.cllc.2024.02.005_bib0010","doi-asserted-by":"crossref","first-page":"A12","DOI":"10.7326\/ACPJC-1995-123-3-A12","article-title":"The well-built clinical question: a key to evidence-based decisions","volume":"123","author":"Richardson","year":"1995","journal-title":"ACP J Club"},{"key":"10.1016\/j.cllc.2024.02.005_bib0011","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1472-6947-7-16","article-title":"Utilization of the PICO framework to improve searching PubMed for clinical questions","volume":"7","author":"Schardt","year":"2007","journal-title":"BMC Med Inform Decis Mak"},{"key":"10.1016\/j.cllc.2024.02.005_bib0012","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/ijc.33119","article-title":"Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors","volume":"147","author":"Abu Rmilah","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cllc.2024.02.005_bib0023","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0028","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s10637-019-00887-0","article-title":"Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer","volume":"38","author":"Tan","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.cllc.2024.02.005_bib0029","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0031","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/pds.5193","article-title":"Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: a post-authorization safety cohort study conducted in Europe and in the United States","volume":"30","author":"Ehrenstein","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.cllc.2024.02.005_bib0032","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.cllc.2012.03.004","article-title":"A phase ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer","volume":"13","author":"Felip","year":"2012","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2024.02.005_bib0033","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1158\/1078-0432.CCR-13-2235","article-title":"A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors","volume":"20","author":"Gray","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2024.02.005_bib0034","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1158\/1078-0432.CCR-15-2218","article-title":"Phase I dose-escalation study of linsitinib (OSI-906) and erlotinib in patients with advanced solid tumors","volume":"22","author":"Macaulay","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2024.02.005_bib0035","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1200\/JCO.2011.39.4882","article-title":"Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer","volume":"30","author":"Schaake","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0036","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/jjco\/hyt056","article-title":"Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803)","volume":"43","author":"Yamada","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0037","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.2010.28.5981","article-title":"Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer","volume":"29","author":"Natale","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0038","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1200\/JCO.2011.39.9782","article-title":"Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer","volume":"30","author":"P\u00e9rol","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0039","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2024.02.005_bib0040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2024.02.005_bib0043","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/01243894-200701000-00006","article-title":"Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer","volume":"2","author":"Yoshida","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0044","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/sj.bjc.6603393","article-title":"A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations","volume":"95","author":"Asahina","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2024.02.005_bib0045","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cllc.2011.02.004","article-title":"Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study","volume":"12","author":"Asami","year":"2011","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2024.02.005_bib0046","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/bjc.2013.721","article-title":"First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study","volume":"110","author":"Douillard","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2024.02.005_bib0047","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.2005.05.4692","article-title":"Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations","volume":"24","author":"Inoue","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0048","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1200\/JCO.2008.18.7658","article-title":"First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy","volume":"27","author":"Inoue","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0049","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1097\/JTO.0b013e318260de8b","article-title":"First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study","volume":"7","author":"Maemondo","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0053","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1200\/JCO.2007.14.8494","article-title":"First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations","volume":"26","author":"Sequist","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0050","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.lungcan.2008.09.010","article-title":"Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations","volume":"64","author":"Sugio","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2024.02.005_bib0051","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.lungcan.2007.01.025","article-title":"Phase II prospective study of the efficacy of gefitinib for the treatment of stage III\/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy","volume":"56","author":"Sunaga","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2024.02.005_bib0052","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/sj.bjc.6603466","article-title":"Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp","volume":"95","author":"Sutani","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2024.02.005_bib0054","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2011.36.8456","article-title":"First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung","volume":"30","author":"Han","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0055","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/ijc.30806","article-title":"Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: a randomized controlled trial","volume":"141","author":"Han","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cllc.2024.02.005_bib0056","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1200\/JCO.2009.23.3445","volume":"28","author":"Takeda","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0057","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S1470-2045(12)70117-1","article-title":"Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial","volume":"13","author":"Zhang","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0059","doi-asserted-by":"crossref","first-page":"e95897","DOI":"10.1371\/journal.pone.0095897","article-title":"Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cllc.2024.02.005_bib0060","first-page":"90","article-title":"Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer","volume":"25","author":"Gu","year":"2013","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.cllc.2024.02.005_bib0061","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s12013-014-9955-y","article-title":"Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes","volume":"70","author":"Pan","year":"2014","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.cllc.2024.02.005_bib0062","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/1759-7714.12085","article-title":"Efficacy of icotinib treatment in patients with stage IIIb\/IV non-small cell lung cancer","volume":"5","author":"Qin","year":"2014","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.cllc.2024.02.005_bib0063","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3760\/cma.j.issn.0366-6999.20131290","article-title":"Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy","volume":"127","author":"Shao","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.cllc.2024.02.005_bib0064","doi-asserted-by":"crossref","first-page":"929","DOI":"10.2147\/OTT.S98363","article-title":"Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer","volume":"9","author":"Shen","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.cllc.2024.02.005_bib0065","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.2147\/OTT.S93823","article-title":"Effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes","volume":"9","author":"Wang","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.cllc.2024.02.005_bib0066","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.4761","article-title":"Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion\u2013positive metastatic non\u2013small cell lung cancer: a phase 1\/2 open-label nonrandomized clinical trial","volume":"7","author":"Zhou","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0069","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1016\/S1556-0864(16)30243-X","article-title":"Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose [abstract 1300]","volume":"11","author":"Park","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0070","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/cncr.33385","article-title":"Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: a global, phase 2 study","volume":"127","author":"Park","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2024.02.005_bib0071","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2020.02.003","article-title":"Cardiac adverse events in EGFR-mutated non-small cell lung cancer treated with osimertinib","volume":"2","author":"Kunimasa","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0072","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/jjco\/hyaa067","article-title":"Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan","volume":"50","author":"Ohe","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0073","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","article-title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study","volume":"17","author":"Goss","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0074","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2024.02.005_bib0075","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","article-title":"Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study","volume":"21","author":"Sequist","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0076","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","article-title":"Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component","volume":"35","author":"Yang","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0077","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1158\/1078-0432.CCR-20-1690","article-title":"Phase I study of the efficacy and safety of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant non-small cell lung cancer","volume":"27","author":"Yu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2024.02.005_bib0078","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2024.02.005_bib0079","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2024.02.005_bib0081","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.2147\/CMAR.S189626","article-title":"Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase ib trial","volume":"11","author":"Hu","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.cllc.2024.02.005_bib0013","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12890-020-01217-4","article-title":"A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin","volume":"20","author":"Bian","year":"2020","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.cllc.2024.02.005_bib0014","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s13691-020-00450-2","article-title":"Osimertinib-induced cardiac failure with QT prolongation and torsade de pointes in a patient with advanced pulmonary adenocarcinoma","volume":"10","author":"Ikebe","year":"2021","journal-title":"Int Cancer Conf J"},{"key":"10.1016\/j.cllc.2024.02.005_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.655808","article-title":"Case report: QT prolongation and abortive sudden death observed in an 85-year-old female patient with advanced lung cancer treated with tyrosine kinase inhibitor osimertinib","volume":"8","author":"Kondo","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cllc.2024.02.005_bib0016","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1200\/JCO.20.01171","article-title":"Cardiac safety of osimertinib: a review of data","volume":"39","author":"Ewer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0017","first-page":"3","article-title":"Cardiac safety of afatinib: a review of data from clinical trials","volume":"1","author":"Ewer","year":"2015","journal-title":"Cardiooncology"},{"key":"10.1016\/j.cllc.2024.02.005_bib0018","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1536\/ihj.21-130","article-title":"Erlotinib-induced cardiomyopathy in a patient with metastatic non-small cell lung cancer","volume":"62","author":"Nagashio","year":"2021","journal-title":"Int Heart J"},{"key":"10.1016\/j.cllc.2024.02.005_bib0019","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000444186","article-title":"Maintenance treatment by erlotinib and toxic cardiomyopathy: a case report","volume":"90","author":"Pinqui\u00e9","year":"2016","journal-title":"Oncology"},{"key":"10.1016\/j.cllc.2024.02.005_bib0020","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jaccas.2019.12.038","article-title":"Osimertinib-induced cardiomyopathy","volume":"2","author":"Patel","year":"2020","journal-title":"JACC Case Rep"},{"key":"10.1016\/j.cllc.2024.02.005_bib0021","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jaccao.2020.01.003","article-title":"Heart failure associated with the epidermal growth factor receptor inhibitor osimertinib","volume":"2","author":"Piper-Vallillo","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0022","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.2169\/internalmedicine.8344-16","article-title":"Congestive heart failure during osimertinib treatment for epidermal growth factor receptor (EGFR): mutant non-small cell lung cancer (NSCLC)","volume":"56","author":"Watanabe","year":"2017","journal-title":"Intern Med"},{"key":"10.1016\/j.cllc.2024.02.005_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2020.100594","article-title":"QT interval prolongation related to afatinib treatment in a patient with metastatic non-small-cell lung cancer","volume":"44","author":"Demircan","year":"2020","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.cllc.2024.02.005_bib0025","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1470-2045(12)70087-6","article-title":"Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b\/3 randomised trial","volume":"13","author":"Miller","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0026","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0027","year":"2022"},{"key":"10.1016\/j.cllc.2024.02.005_bib0030","year":"2020"},{"key":"10.1016\/j.cllc.2024.02.005_bib0042","year":"2016"},{"key":"10.1016\/j.cllc.2024.02.005_bib0058","year":"2023"},{"key":"10.1016\/j.cllc.2024.02.005_bib0067","year":"2023"},{"key":"10.1016\/j.cllc.2024.02.005_bib0080","year":"2022"},{"key":"10.1016\/j.cllc.2024.02.005_bib0068","unstructured":"Tagrisso (AZD9291) approved by the US FDA for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer [press release]: AstraZeneca; 13 Nov 2015. Available at: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2015\/TAGRISSO-AZD9291-approved-by-the-US-FDA-for-patients-with-EGFR-T790M-mutation-positive-metastatic-non-small-cell-lung-cancer-13112015.html#. Accessed 22 August 2022."},{"key":"10.1016\/j.cllc.2024.02.005_bib0082","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.lungcan.2020.12.011","article-title":"Afatinib in EGFR TKI-na\u00efve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: interim analysis of a phase 3b study","volume":"152","author":"de Marinis","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2024.02.005_bib0083","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1200\/JCO.2012.45.0981","article-title":"LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both","volume":"31","author":"Katakami","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0084","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1470-2045(12)70086-4","article-title":"Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial","volume":"13","author":"Yang","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0085","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0086","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/annonc\/mdv597","article-title":"Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib\/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial","volume":"27","author":"Schuler","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0087","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/cncr.28561","article-title":"A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib","volume":"120","author":"Reckamp","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2024.02.005_bib0088","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2013.07.003","article-title":"A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)","volume":"82","author":"Goto","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2024.02.005_bib0089","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1158\/1078-0432.CCR-06-0112","article-title":"A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer","volume":"12","author":"Reckamp","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2024.02.005_bib0090","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1200\/JCO.2011.40.1315","article-title":"Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial","volume":"30","author":"J\u00e4nne","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0091","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1200\/JCO.2008.21.5541","article-title":"Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer","volume":"27","author":"Mok","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0092","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0103","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/annonc\/mdv270","article-title":"First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study","volume":"26","author":"Wu","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0094","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0107","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1200\/JCO.2007.15.0672","article-title":"Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study","volume":"26","author":"Crin\u00f2","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0108","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2004.07.215","article-title":"Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial\u2013INTACT 2","volume":"22","author":"Herbst","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0109","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.cllc.2024.02.005_bib0110","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1158\/1078-0432.CCR-09-1903","article-title":"Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy","volume":"16","author":"Lee","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2024.02.005_bib0111","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med."},{"key":"10.1016\/j.cllc.2024.02.005_bib0112","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1200\/JCO.2007.15.0185","article-title":"Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer","volume":"26","author":"Maruyama","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0113","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0099","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(13)70355-3","article-title":"Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial","volume":"14","author":"Shi","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0096","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2014.08.014","article-title":"A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)","volume":"86","author":"Hu","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2024.02.005_bib0097","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142500","article-title":"The efficacy and safety of icotinib in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a single-arm, multi-center, prospective study","volume":"10","author":"Hu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cllc.2024.02.005_bib0098","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S2213-2600(21)00134-X","article-title":"Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial","volume":"9","author":"He","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cllc.2024.02.005_bib0100","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.lungcan.2019.07.007","article-title":"Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: a single arm, open label, phase 1\/2 trial","volume":"135","author":"Kim","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2024.02.005_bib0101","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annonc.2020.01.013","article-title":"TATTON: a multi-arm, phase ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer","volume":"31","author":"Oxnard","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0102","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s11523-021-00806-5","article-title":"Savolitinib \u00b1 osimertinib in Japanese patients with advanced solid malignancies or EGFRm NSCLC: Ph1b TATTON part C","volume":"16","author":"Yoh","year":"2021","journal-title":"Target Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0093","doi-asserted-by":"crossref","first-page":"S1077","DOI":"10.1016\/j.jtho.2019.08.2398","article-title":"QT Prolongation in an EGFR 19 Deletion Lung Adenocarcinoma Patient from Icotinib Treatment [abstract EP1.16-33]","volume":"14","author":"Wu","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0104","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2015.64.0409","article-title":"Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study","volume":"34","author":"Armenian","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.02.005_bib0105","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(19)31674-5","article-title":"Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases","volume":"394","author":"Strongman","year":"2019","journal-title":"Lancet"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424000160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424000160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T07:15:15Z","timestamp":1716966915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730424000160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":110,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1525730424000160"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2024.02.005","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"QT-Interval Prolongation, Torsades de Pointes, and Heart Failure With EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2024.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Takeda Development Center Americas, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}